A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Fulvestrant (Primary) ; INX 315 (Primary)
Indications Advanced breast cancer; Fallopian tube cancer; HER2 negative breast cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors Incyclix Bio

13 Dec 2024 According to an Incyclix Bio media release, company the data were presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).
13 Dec 2024 Interim results presented in the Incyclix Bio Media Release.
18 Nov 2024 According to an Incyclix Bio media release, company plans to initiate combination cohorts with INX-315 in fourth quarter of 2024. This combination therapy to be evaluated as part of ongoing Phase 1/2 study in patients with HR+/HER2- metastatic breast cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com